Unmet Needs in the Management of Advanced RCC
Drs Alter and Diamond muse about the unmet needs in advanced RCC treatment.
Cabozantinib + Nivolumab Regimen in the Treatment of Advanced RCC
A discussion on the role of the cabozantinib and nivolumab regimen in the treatment of advanced RCC.
Patient Profile Presentation: A 56-Year-Old Man with Clear Cell RCC
Robert Alter, MD, presents the patient profile of a 56-year-old man with clear cell renal cell carcinoma presenting with hip and leg pain.
Advanced RCC Patient Referrals from Community Oncologists
Elan Diamond, MD, describes when and how often community oncologists refer patients with suspected advanced renal cell carcinoma to his practice.
Nivolumab + Ipilimumab Combination Regimen for Advanced RCC
Oncologists review the IO/IO combination regimens available for treatment of advanced RCC and discuss patient selection for treatment with nivolumab and ipilimumab.
Patient Profile Presentation: A 70-Year-Old Man with Stage 4 Clear Cell RCC
Dr Elan Diamond presents the patient profile of a 70-year-old man with stage IV clear cell renal cell carcinoma.
Sequencing Therapies for Advanced RCC
Experts discuss how they sequence I/O–TKI treatments for advanced renal cell carcinoma.
Toxicities with IO-TKI Combination Regimens for Advanced RCC and Their Management
Elan Diamond, MD, explains toxicities commonly seen with I/O–TKI combination regimens, how to manage them, and how to discuss toxicities with patients with advanced renal cell carcinoma.
Front-Line Lenvatinib + Pembrolizumab Combination Regimens for Advanced RCC: Selecting Patients and Dose
A review of the first-line I/O-TKI combination regimens available for advanced RCC and selecting the right patients and dose for treatment with lenvatinib and pembrolizumab.
Patient Profile Presentation: A 56-Year-Old Man with Metastatic Clear Cell RCC
Robert Alter, MD, presents the patient profile of a 56-year-old man with metastatic clear cell renal cell carcinoma presenting with chromaturia.
Dr. Alter Discusses Provenge MOA and Tolerability
Dr. Robert Alter from John Theurer Cancer Center Discusses Provenge MOA and Tolerability
Dr. Alter Discusses the Provenge Treatment Process
Dr. Robert Alter from John Theurer Cancer Center Discusses the Provenge Treatment Process
Dr. Alter Discusses the Immunotherapy Provenge
Dr. Robert Alter from John Theurer Cancer Center Discusses the Immunotherapy Provenge
Dr. Alter on Trials and Ongoing Research in Kidney Cancer
Robert S. Alter, M.D. Co-chief, Urologic Oncology, John Theurer Cancer Center, on major trials and ongoing research in kidney cancer, in the spring of 2011.
Dr. Alter on Kidney Injury in Relation to Patient Recovery
Dr. Robert Alter on ASCO GU-Kidney Cancer Findings
Dr. Alter on 2011 ASCO GU Prostate Cancer Findings
Robert S. Alter, M.D. Co-chief, Urologic Oncology, John Theurer Cancer Center, on prostate cancer research that was presented at the 2011 ASCO Genitourinary meeting.
Dr. Alter Discusses Research at JTCC
Dr. Robert Alter on Current Research at John Theurer Cancer Center
Dr. Alter on Kidney Cancer Drugs From 2005-2010
Robert S. Alter, MD, Co-chief, Urologic Oncology, John Theurer Cancer Center, on kidney cancer drugs from the year 2005 to 2010.
Dr Graff on the Relation Between ctDNA Positivity and Disease Recurrence in HR+/HER2– Breast Cancer
Dr Damodaran on Futibatinib Plus Fulvestrant in FGFR1-Amplified HR+/HER2– Breast Cancer
Trastuzumab Deruxtecan Plus Endocrine Therapy Demonstrates Antitumor Activity in HER2-Low/HR+ Metastatic Breast Cancer
T-DXd Yields Early Activity in HER2+/HER2-Low Breast Cancer With Leptomeningeal Carcinomatosis
2 Clarke Drive Cranbury, NJ 08512